Form 4 for ALLO Allogene Therapeutics, Inc.
Accepted 2025-02-20 00:00:00 ET · period of report 2025-02-18 · accession 0001737287-25-000022 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-20 | 2025-02-18 | ALLO | MESSEMER DEBORAH M. | Dir | S - Sale | $2.43 | -13.3K | 144.3K | -8% | -$32.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-18 | S | D | 13,313 | $2.43 | 144,316 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $2.42 to $2.44, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |